Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides…
Medical - Diagnostics & Research
US, Menlo Park [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Personalis, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | - | -0.990 | - | 64 | - | -47 | - | -46 | - | -49 | - | 38 |
| 2020 | -0.8000 | -1.133 | 65 | 78 | -25 | -39 | -18 | -33 | -22 | -40 | 22 | 32 |
| 2021 | -1.0600 | -1.530 | 78 | 85 | -41 | -71 | -34 | -64 | -42 | -71 | 33 | 52 |
| 2022 | -1.4900 | -2.454 | 85 | 65 | -65 | -98 | -59 | -90 | -65 | -99 | 47 | 60 |
| 2023 | -2.4800 | -2.212 | 65 | 73 | -113 | -108 | -104 | -103 | -115 | -113 | 63 | 69 |
| 2024 | - | -1.436 | - | 84 | - | -68 | - | -57 | - | -62 | - | 50 |
| 2025 | - | -1.037 | - | 87 | - | -49 | - | -59 | - | -64 | - | 52 |
| 2026 | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
| 2027 | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
| 2028 | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |